e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?
Tiziana Masini, Janika Hauser, Rutendo Kuwana, Nguyen Nhat Linh, Ernesto Jaramillo
Source:
Eur Respir J, 51 (3) 1702480; 10.1183/13993003.02480-2017
Journal Issue:
March
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Tiziana Masini, Janika Hauser, Rutendo Kuwana, Nguyen Nhat Linh, Ernesto Jaramillo. Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?. Eur Respir J, 51 (3) 1702480; 10.1183/13993003.02480-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The sustainability agenda and inhaled therapy: what do patients want?
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Pros: governments should impose targets for healthcare professionals to switch their respiratory disease patients to inhalers with a low global warming potential
Source: International Congress 2019 – Recent clinical advances in inhalation therapy
Year: 2019
Getting the rehabilitation message across: emerging barriers and positive health benefits
Source: Eur Respir J 2009; 34: 2-4
Year: 2009
Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects
Source: International Congress 2017 – In the frontline of the fight against tuberculosis
Year: 2017
Cons - governments should impose targets for healthcare professionals to switch their respiratory disease patients to inhalers with a low global warming potential
Source: International Congress 2019 – Recent clinical advances in inhalation therapy
Year: 2019
Do we need new antibiotics?
Source: Annual Congress 2009 - Antibiotics and the lung
Year: 2009
Getting approval for new therapeutic medical devices versus drugs: are the differences justified?
Source: Eur Respir Rev 2016; 25: 223-226
Year: 2016
The issues and the controversies: are we really ready for on-demand use of ICS?
Source: Annual Congress 2013 –Inhaled corticosteroids for asthma: on-demand or continuous use?
Year: 2013
The effect of respiratory comorbidities on the provision of cessation assistance in six EU countries: are clinicians doing enough?
Source: International Congress 2018 – EUREST-PLUS: implementation of the tobacco control policy to reduce lung disease
Year: 2018
Preventing skin care issues associated with face masks used for domiciliary non-invasive ventilation: what do users and their carers think are the most relevant future research questions?
Source: International Congress 2019 – Treatment of chronic respiratory failure with noninvasive ventilation
Year: 2019
What are the knowledge gaps in COPD that prevent new drug development?
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014
MDR-/XDR-TB: what are the unresolved problems in the clinical management?
Source: Annual Congress 2012 - PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up (TB PAN-NET)
Year: 2012
Do users want to be involved in respiratory service development?
Source: Eur Respir J 2004; 24: Suppl. 48, 66s
Year: 2004
Crowdfunding for respiratory research: a new frontier for patient and public engagement?
Source: Eur Respir J, 50 (4) 1701333; 10.1183/13993003.01333-2017
Year: 2017
The benefits and challenges of involving patients as project partners: the professional perspective
Source: International Congress 2015 – Involve patients in research projects
Year: 2015
Who can pay for innovative medicines?
Source: Eur Respir J 2013; 41: 495-496
Year: 2013
Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance
Source: Eur Respir J 2012; 39: 802-804
Year: 2012
Strategies to effectively communicate science to patients and the wider public
Source: International Congress 2019 – Effective communication of scientific findings
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept